Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy
- 1 January 2022
- journal article
- research article
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 18 (1) , 235-244
Abstract
This post-hoc analysis characterized the weekly incidence and overall duration of common early-onset treatment-emergent adverse events (TEAEs) during solriamfetol treatment. Participants (obstructive sleep apnea [OSA], N=474; narcolepsy, N=236) were randomized to 12 weeks of placebo or solriamfetol 37.5 (OSA only), 75, 150, or 300 mg. For common early-onset TEAEs (those occurring in ≥5% of participants in any solriamfetol dose group and with a higher incidence than that observed in placebo-treated participants during week 1), the incidence of new occurrence or change in severity over time was calculated for each subsequent study week. Data were analyzed separately for each study and summarized by placebo and combined solriamfetol groups. Common early-onset TEAEs (at doses ≤150 mg, ie, approved doses) included headache (OSA, 5.1%; narcolepsy, 8.5%), nausea (OSA, 2.5%; narcolepsy, 4.2%), decreased appetite (OSA, 4.2%; narcolepsy, 5.9%), as well as anxiety (2.1%), insomnia (1.3%), and feeling jittery (3.0%) in OSA and dry mouth (4.2%) in narcolepsy. Incidence of common early-onset TEAEs was highest at week 1 and decreased over time. In OSA at doses ≤150 mg, headache, nausea, and feeling jittery had median durations ≤8 days, whereas decreased appetite, anxiety, and insomnia had longer durations. In narcolepsy at doses ≤150 mg, headache and nausea had median durations ≤8 days, whereas decreased appetite and dry mouth had longer durations. Most TEAEs were mild to moderate in severity. Common early-onset TEAEs with solriamfetol are limited in duration, with the majority subsiding during the first week of treatment. NCT02348593; NCT02348606.Keywords
This publication has 22 references indexed in Scilit:
- Treatment Options for NarcolepsyCNS Drugs, 2016
- Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-AnalysisJournal of Clinical Sleep Medicine, 2015
- Obstructive sleep apnoea syndromeNature Reviews Disease Primers, 2015
- Clinical and practical considerations in the pharmacologic management of narcolepsySleep Medicine, 2015
- Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trialThe Lancet Neurology, 2013
- Residual sleepiness in sleep apnea patients treated by continuous positive airway pressureJournal of Sleep Research, 2013
- Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre studyEuropean Respiratory Journal, 2009
- Prevalence of narcolepsy in King County, Washington, USASleep Medicine, 2009
- Hypocretin Deficiency in Narcoleptic Humans Is Associated with Abdominal ObesityObesity Research, 2003
- The Epidemiology of Narcolepsy in Olmsted County, Minnesota: A Population-Based StudySLEEP, 2002